Showing results (241-250 of 259) with videos related to
Sort By:
Pageof 26
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.JTO Clinical and Research Reports|January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)Aaron C Tan, Bin-Chi Liao, Molly Li, et al.The New England Journal of Medicine|October 4, 2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung CancerD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without AmivantamabZofia Piotrowska, Antonio Passaro, Danny Nguyen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2026
Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibodyBen Tran, Mark Voskoboynik, Sang-We Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical PracticeXiuning Le, Hiroshi Sakai, Enriqueta Felip, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
Amivantamab Plus Lazertinib in Atypical <i>EGFR</i>-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2Pascale Tomasini, Yongsheng Wang, Yongsheng Li, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSASe-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.American Journal of Respiratory and Critical Care Medicine|September 27, 2016
Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase InhibitorsI-Shou Chang, Shih Sheng Jiang, James Chih-Hsin Yang, et al.Pageof 26